GlassScriptPhysician profile
Thomas M Newman
NPI 1205884111
$3,138.51
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $1,667 · 2021: $71.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $432.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $304.85 | 2019-2020 | |
| Genzyme Corporation | $221.81 | 2019-2020 | |
| Biogen, INC. | $151.71 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $137.45 | 2019-2020 | |
| Amgen INC. | $133.39 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $125.71 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $116.64 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $110.58 | 2019-2020 | |
| Ucb, INC. | $105.98 | 2019-2020 | |
| Acorda Therapeutics, INC | $103.86 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $100.39 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $99.41 | 2020 | |
| Vanda Pharmaceuticals INC. | $98.91 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $90.21 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $78.68 | 2019-2020 | |
| Tanabe Pharma America, INC. | $70.67 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $64.72 | 2019-2020 | |
| Genentech USA, INC. | $59.13 | 2019 | |
| Emd Serono, INC. | $50.52 | 2020 | |
| Mdd US Operations, LLC | $50.24 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $46.61 | 2019 | |
| Acadia Pharmaceuticals INC | $38.35 | 2019 | |
| Abbvie INC. | $36.20 | 2019-2020 | |
| Tersera Therapeutics LLC | $35.64 | 2019 | |
| Lilly USA, LLC | $34.46 | 2019-2021 | |
| Lundbeck LLC | $34.29 | 2019-2020 | |
| Neos Therapeutics, LP | $33.54 | 2020 | |
| Zyla Life Sciences, INC. | $29.43 | 2020 | |
| Bausch Health US, LLC | $23.37 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.87 | 2020 | |
| Adlon Therapeutics L.P. | $20.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.65 | 2020 | |
| Pfizer INC. | $14.89 | 2019 | |
| Assertio Therapeutics, INC. | $14.35 | 2019 | |
| Currax Pharmaceuticals LLC | $13.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.